UroGen Pharma (URGN) stock: insider trades, news & valuation
Heavy sellingShare price and insider trades
UroGen Pharma insider trading at a glance (Oct 9, 2026): in the past 12 months, 0 insiders bought $0 and 3 sold $4.8M of URGN stock on the open market.
Get emailed when insiders cluster-buy stocks like URGN
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
URGN insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | $81K | 1 |
| Q3 2026 | — | 0 | $3.4M | 4 |
| Q2 2026 | — | 0 | $793K | 3 |
| Q1 2026 | — | 0 | $292K | 6 |
| Q4 2025 | — | 0 | $287K | 2 |
Valuation, profit and volume
Summary
Over the past 12 months, 0 UroGen Pharma Ltd. insiders reported open-market purchases totaling $0, while 3 insiders reported sales totaling $4.8M. 4 of 16 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Oct 9 NewSEC | Chris DegnanCFO | Sell | 2,2024,561 held (−33%) | $36.69 | $81K | +0.4% | — |
| Sep 9SEC | Jason Drew SmithGeneral Counsel | Sell | 1,51953,141 held (−3%) | $42.54 | $65K | -13.4% | — |
| Sep 9SEC | Mark SchoenbergChief Medical Officer | Sell | 87159,882 held (−1%) | $42.92 | $37K | -14.2% | — |
| Aug 24SEC | Mark SchoenbergChief Medical Officer | Sell | 60,67759,086 held (−51%) | $47.05 | $2.9M | -21.7% | — |
| Jul 10SEC | Mark SchoenbergChief Medical Officer | Sell Plan | 10,000119,763 held (−8%) | $40.00 | $400K | -7.9% | — |
| Jun 24SEC | Mark SchoenbergChief Medical Officer | Sell Plan | 10,000129,763 held (−7%) | $35.01 | $350K | +5.2% | — |
| Jun 9SEC | Mark SchoenbergChief Medical Officer | Sell | 5,222139,763 held (−4%) | $27.30 | $143K | +34.9% | — |
| May 11SEC | Mark SchoenbergChief Medical Officer | Sell Plan | 10,000134,985 held (−7%) | $30.00 | $300K | +22.8% | — |
| Feb 11SEC | Jason Drew SmithGeneral Counsel | Sell | 3,21755,588 held (−5%) | $19.69 | $63K | +87.0% | — |
| Feb 11SEC | Jason Drew SmithGeneral Counsel | Sell | 2,65452,934 held (−5%) | $19.69 | $52K | +87.0% | — |
| Feb 11SEC | Jason Drew SmithGeneral Counsel | Sell | 1,60851,326 held (−3%) | $19.69 | $32K | +87.0% | — |
| Feb 4SEC | Mark SchoenbergChief Medical Officer | Sell | 3,686144,985 held (−2%) | $19.69 | $73K | +87.0% | — |
| Feb 4SEC | Mark SchoenbergChief Medical Officer | Sell | 1,844150,514 held (−1%) | $19.69 | $36K | +87.0% | — |
| Feb 4SEC | Mark SchoenbergChief Medical Officer | Sell | 1,843148,671 held (−1%) | $19.69 | $36K | +87.0% | — |
| Nov 20SEC | Mark SchoenbergChief Medical Officer | Sell Plan | 10,000139,025 held (−7%) | $25.00 | $250K | +47.3% | — |
| Oct 9SEC | Chris DegnanCFO | Sell | 2,2032,280 held (−49%) | $16.85 | $37K | +118.6% | — |
Insiders at UroGen Pharma Ltd.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Mark SchoenbergChief Medical Officer | — | $4.5M | Sep 9, 2026 | — |
| Jason Drew SmithGeneral Counsel | — | $212K | Sep 9, 2026 | — |
| Chris DegnanCFO | — | $118K | Oct 9, 2026 | — |
URGN stock: common questions
Are UroGen Pharma Ltd. insiders buying URGN stock?
In the past 12 months, 0 insiders reported open-market purchases of URGN worth $0.
Are UroGen Pharma Ltd. insiders selling URGN stock?
3 insiders reported sales worth $4.8M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is URGN's 52-week range?
Over the past year URGN has traded between $16.42 and $50.29. It last closed at $36.83 on Oct 9, 2026.